profession
live
wit
healthcar
crisi
magnitud
sever
proof
march
caus
viru
label
global
pandem
world
health
organ
sweep
across
case
death
case
report
countri
number
rise
substanti
forthcom
week
month
midst
nation
local
driven
crisi
manag
plan
understand
impact
routin
practic
priorit
acut
care
vulner
felt
time
highlight
area
disciplinespecif
contribut
deliv
major
impact
first
patient
treat
glucocorticoid
invalu
reiter
sick
day
rule
known
patient
primari
secondari
adren
insuffici
take
glucocorticoid
replac
therapi
relat
patient
dri
continu
cough
fever
immedi
doubl
daili
oral
glucocorticoid
dose
continu
regimen
fever
subsid
deterior
patient
experi
vomit
diarrhea
seek
urgent
medic
care
treat
parenter
glucocorticoid
impact
extens
guidelin
patient
popul
take
chronic
therapeut
corticosteroid
differ
rout
underli
inflammatori
condit
preval
adren
insuffici
patient
high
irrespect
mode
deliveri
current
littl
evid
guid
us
interven
term
durat
prior
corticosteroid
exposur
impact
dose
either
higher
dose
supplement
steroid
cover
may
necessari
lower
dose
adren
suppress
may
preval
interim
seem
logic
essenti
identifi
patient
take
corticosteroid
whatev
reason
high
risk
know
publish
report
date
patient
overrepres
greatest
risk
die
elderli
comorbid
includ
diabet
hypertens
chronic
inflammatori
diseas
moreov
patient
take
supraphysiolog
dose
glucocorticoid
may
increas
suscept
result
immunosuppress
effect
steroid
comorbid
underli
immun
disord
steroid
prescrib
immunomodulatori
action
therapi
prescrib
conjunct
glucocorticoid
underli
diseas
revers
potenti
adren
failur
caus
mortal
parenter
glucocorticoid
therapi
easi
simpl
issu
recogn
intent
ensur
patient
histori
prior
exposur
chronic
glucocorticoid
therapi
month
whatev
rout
die
without
consider
parenter
glucocorticoid
therapi
commun
key
ensur
recognit
manag
implement
import
measur
context
import
commun
reason
underpin
glucocorticoid
use
base
prior
experi
patient
acut
respiratori
distress
syndrom
affect
sar
mer
glucocorticoid
therapi
without
benefit
associ
higher
rate
invas
ventil
mortal
world
health
organ
guidanc
prescrib
glucocorticoid
physiolog
stress
dose
hydrocortison
mg
intraven
tid
pharmacolog
dose
corticosteroid
given
second
impact
patient
pituitari
neuroendocrin
diseas
also
need
consid
patient
primari
adren
insuffici
mani
patient
hypopituitar
includ
secondari
adren
insuffici
requir
stress
dose
glucocorticoid
supplement
previous
note
moreov
patient
may
also
diabet
insipidu
compound
fluid
electrolyt
disord
requir
care
monitor
judici
water
electrolyt
replac
prevent
hyponatremia
hypernatremia
particularli
import
context
increas
insens
fluid
loss
associ
fever
tachypnea
combin
impair
abil
fluid
intak
alter
level
conscious
third
patient
diabet
mellitu
wherea
risk
contract
viral
ill
greater
without
diabet
mellitu
sever
diseas
viral
infect
notabl
greater
recent
publish
report
wuhan
provinc
china
reveal
diabet
mellitu
hypertens
overrepres
among
sever
ill
patient
succumb
diseas
whether
suscept
ill
sever
especi
greater
case
simpli
reflect
greater
risk
pose
diabet
remain
uncertain
point
current
guidanc
center
diseas
control
prevent
prevent
diabet
differ
gener
popul
recognit
diabet
pose
greater
risk
sever
ill
prompt
healthcar
provid
vigil
assess
patient
present
concern
symptom
ie
short
breath
fever
final
clinician
scientist
realiz
research
innov
ultim
provid
solut
crisi
whether
enhanc
diagnost
innov
therapi
futur
vaccin
potenti
excit
endocrineconnect
observ
elucid
mechan
entri
cell
angiotensinconvert
enzym
establish
sarscov
receptor
conflict
data
translat
relev
suggest
angiotensinconvert
enzym
inhibitorsangiotensin
receptor
blocker
might
increas
suscept
sever
upregul
therebi
possibl
explain
overrepresent
hypertens
patient
patient
die
upregul
might
also
explain
poor
outcom
smoker
versu
nonsmok
import
stress
preliminari
report
result
chang
prescrib
medic
stage
recombin
human
develop
apeiron
treatment
acut
lung
injuri
acut
respiratori
distress
syndrom
pulmonari
arteri
hypertens
slow
viral
entri
cell
viral
spread
may
benefici
clinic
trial
underway
convers
angiotensin
ii
known
stimul
alveolar
epitheli
cell
apoptosi
inhibit
angiotensin
receptor
blocker
losartan
might
reduc
mortal
acut
respiratori
distress
syndrom
infect
perhap
justifi
greater
excit
downstream
transmembran
proteas
serin
requir
viral
spike
protein
prime
onward
transmiss
camostat
mesyl
transmembran
proteas
serin
inhibitor
approv
japan
treatment
pancreat
inflamm
test
isol
patient
prevent
entri
viru
lung
cell
endocrinerel
target
forefront
discoveri
scienc
collect
tackl
pandem
